Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - ASSEMBLY BIOSCIENCES, INC. | v240385_ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - ASSEMBLY BIOSCIENCES, INC. | v240385_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14, 2011
|
VENTRUS BIOSCIENCES, INC.
|
||
|
(Exact name of registrant as specified in its charter)
|
|
Delaware
|
001-35005
|
20-8729264
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer ID Number)
|
|
99 Hudson Street, 5th Floor, New York, New York 10013
|
|
(Address of principal executive offices) (Zip Code)
|
|
Registrant’s telephone number, including area code
|
(646) 706-5208
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other Events.
Attached hereto as Exhibit 99.1 and 99.2 is a PowerPoint Presentation that Ventrus will present to investors and at various industry events and the hemorrhoid market survey Ventrus posted to its website. Exhibits 99.1 and 99.2 are incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
|
(d)
|
Exhibits
|
|
ExhibitNo.
|
Description
|
|
|
99.1
|
Slide presentation of November 2011 to be presented to investors.
|
|
|
99.2
|
Hemorrhoid market survey summary posted to Ventrus Biosciences, Inc. website.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VENTRUS BIOSCIENCES, INC. | |||
|
Date: November 14, 2011
|
By:
|
/s/ David J. Barrett | |
|
David J. Barrett, Chief Financial Officer
|
|||